comparemela.com

Latest Breaking News On - காப்புரிமை கால நீட்டிப்பு - Page 1 : comparemela.com

Why Obviousness-type Double Patent Analysis Isn t Obvious - Intellectual Property

Why Obviousness-type Double Patent Analysis Isn t Obvious - Intellectual Property
mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.

Obviousness-type Double Patent Analysis Isn t Always Obvious

Obviousness-type Double Patent Analysis Isn t Always Obvious
natlawreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from natlawreview.com Daily Mail and Mail on Sunday newspapers.

Patent Term Extension Introduced by the Fourth Amendment to the Chinese Patent Law | Rothwell, Figg, Ernst & Manbeck, P C

To embed, copy and paste the code into your website or blog: In an earlier post, we discussed the patent linkage system implemented in the Fourth Amendment to the Chinese Patent Law, which will come into effect on June 1, 2021.  Another important change in the amendment is the introduction of Patent Term Extension (PTE) for pharmaceutical patents. The new PTE provision is in the 3 rd paragraph of Article 42 in the amended Chinese Patent Law, which reads and is translated as follows: “In order to compensate for the time taken for regulatory review and approval of a new drug in China, the Patent Administration Department of the State Council, at the request of a patentee, may extend the term of an invention patent related to the new drug that has received regulatory approval for marketing in China. The patent term extension should not exceed five years, and the total remaining term of the patent after the regulatory approval should not exceed fourteen years.”

Why Wall Street Is Worried About Pfizer Despite Its COVID Vaccine Success

Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights Pfizer (NYSE:PFE) just knocked it out of the park with its first-quarter results. Its revenue soared 42% year over year and adjusted earnings per share skyrocketed 48%. The big drugmaker blew away analysts estimates and significantly raised full-year revenue and earnings guidance. You might think that Wall Street would have been enthusiastic about such a strong quarterly update. Nope. Pfizer s shares barely moved after the Q1 results were announced. Mizuho Securities analyst Vamil Divan even

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.